PODDNMSHealthcare·Medical Devices#12 in industry

Insulet Corporation

Reports in 9d· 2026-05-06

-29.1% · 90d

$187.86

-1.71 (-0.90%)

News

(1)

April 2026

Apr 6, 20263 weeks agoDEF 14AHealthcare

INSULET CORP — DEF 14A Filing

PODDINSULET CORP

# 🔥 What This Document Is This is Insulet's **definitive proxy statement (DEF 14A)**. Think of it as the official invitation and information packet for the company's annual shareholder meeting. It's required by the SEC and tells you everything you need to know to vote your shares. 👉 **Why it mat

Read summaryView on SEC EDGAR

Key Data

Market Cap$13.01B

Open$188.76

Prev Close$189.56

Day Range$187.59 – $192.12

52W Range$186.25 – $354.88

Volume285,375

P/E (TTM)53.83

EPS$3.49

Dividend Yield—

Beta1.47

Profit Margin9.12%

Revenue Growth31.20%

Price Target$326.35(+73.7%)

Next Earnings2026-05-06(9d)

Analyst Ratings

Strong Buy24 analysts

Buy 20Hold 3Sell 1

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Healthcare · Medical Devices

5,400 employees

www.insulet.com